Shots:
- Eli Lilly has entered into a definitive agreement to acquire SiteOne Therapeutics incl. its asset, STC-004, expanding its pain pipeline
- As per the deal, SiteOne shareholders will receive an upfront payment as well as regulatory & commercial milestones for a total consideration of ~$1B in cash
- STC-004 is a non-opioid Nav1.8 inhibitor, which will advance into a P-II trial for the treatment of chronic pain
Ref: Eli Lilly| Image: SiteOne Therapeutics| Press Release
Related News:- Rznomics Partners with Eli Lilly for RNA Editing Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
